Skip to main content
. 2021 Feb 24;13(5):932. doi: 10.3390/cancers13050932

Figure 3.

Figure 3

(a): Overall survival as a function of receipt of definitive local therapy vs. none in patients with metastatic sarcoma, those surviving >12 months (log rank p < 0.001). (b): Overall survival as a function of receipt of definitive local therapy vs. none in patients with metastatic sarcoma, those surviving >24 months (log rank p < 0.001).